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The structure of GE82832, a translocation inhibitor produced by a soil microorganism, is shown to
be highly related to that of dityromycin, a bicyclodecadepsipeptide antibiotic discovered long ago
whose characterization had never been pursued beyond its structural elucidation. GE82832 and
dityromycin were shown to interfere with both aminoacyl-tRNA and mRNA movement and with
the Pi release occurring after ribosome- and EF-G-dependent GTP hydrolysis. These ﬁndings and
the unusual ribosomal localization of GE82832/dityromycin near protein S13 suggest that the mech-
anism of inhibition entails an interference with the rotation of the 30S subunit ‘‘head’’ which
accompanies the ribosome-unlocking step of translocation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction by modern developments in rational design, fragment based drugIn the last decades the disengagement of the pharmaceutical
companies from antibiotic research and development has resulted
in a dwindling of the antibiotic pipelines, just at the time when the
need for effective antibiotics has dramatically increased by the
emergence and spread of antibiotic-resistant ‘‘superbugs’’ which
are killing hundreds of thousands of people each year [1,2]. To
overcome the drastic shortage of new antibiotics, the world scien-
tiﬁc community is called to make a renewed, focused, possibly
combined effort to tackle the present ‘‘antibiotic emergency’’. After
the initial hopes and the subsequent disappointments generated
by combinatorial chemistry approaches to the generation of new
anti-infectives, it seems clear that the most promising course to
take is that of relying again on natural compounds, which were
and remain the best source of antimicrobials [3–7]. The develop-
ment of smart, high-content screening tests and the use of new
generation libraries is expected to increase the chances of detect-
ing bioactive natural compounds while the potentiality offeredchemical Societies. Published by E
Gualerzi), attilio.fabbretti@u-
rk.
istry, Max Planck Institute ofdiscovery and computational chemistry will be instrumental for
the possible subsequent improvement of the identiﬁed molecules
[8–14].
GE82832 is one of the few antibiotics recently identiﬁed by
screening a library of secondary metabolites produced by soil
microorganisms for bacterial translational inhibitors endowed
with antibacterial activity [15]. GE82832 is produced by
Streptosporangium cinnabarinum (strain GE82832) and consists of
two bioactive isomeric substances (A and B), both having MW
1286 and containing an aromatic and a peptidic part. Functional
tests have shown that GE82832 selectively inhibits exclusively
bacterial protein synthesis in vitro and in vivo; furthermore, it
was demonstrated that this molecule targets the small ribosomal
subunit and inhibits the translocation step of elongation [15].
At the time of its identiﬁcation, the structure of GE82832 had
not been completely solved. Analysis of the physical and chemical
properties of GE82832 suggested that this compound might be
strictly related to the bicyclodecadepsipeptide dityromycin
[16,17], a ‘‘neglected’’ antibiotic [18,19], discovered a long time
ago but whose mechanism of action had never been determined
and whose characterization had never been pursued beyond its
antimicrobial spectrum and its structural elucidation [16,17].
In this study we have further characterized the mechanism of
action and ribosomal localization of GE82832, and compared themlsevier B.V. All rights reserved.
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are structurally and functionally highly related.Fig. 1. Comparison of the inhibitory activities of GE82832 and dityromycin. Effect
of increasing concentrations of GE82832 (d, s) and dityromycin (j, h) on the EF-
G-dependent translocation that allows formation of fMet-Phe-puromycin (d, j)
and on overall mRNA translation (s, h). Further experimental details can be found
in materials ad methods.2. Materials and methods
GE82832 was produced and puriﬁed by Biosearch Italia S.p.A.
Gerenzano (VA), Italy; Dityromycin was a kind gift of Professor S.
O¯mura (Tokyo).
ESI-MS data were recorded on an Ion Trap ESQUIRE 3000 Plus
spectrometer (Bruker, Karlsruhe, Germany) equipped with an LC
Agilent 1100 diode-array detector, using an Ascentis express Supe-
lco RP18, 2.7 lm (50  4.6 mm) column kept at 40 C, eluting at
1 ml min1 with a 7-min linear gradient from 95:5 phase A
[0.05% (v/v) triﬂuoroacetic acid in water]:phase B [0.05% (v/v) tri-
ﬂuoroacetic acid in acetonitrile] to 100% phase B.
2.1. Chemical reactivity tests
(a) Twenty microlitres of GE82832 or dityromycin solution
(2 mg/ml in 20% DMSO) were added to AcOH:37% HCl 25:1 (v/v)
(1 ml), (b) 20 ll of GE82832 or dityromycin solution were added
to AcOH:37% HCl 1:1 (v/v) (1 ml) and (c) 20 ll of GE82832 or dity-
romycin solution were added to NaOH 1 M (1 ml). The solutions
were left at room temperature for 10 min before LC–MS analysis.
2.2. Translation tests
In vitro mRNA translation, tests of individual translational steps,
in situ probing of 16S rRNA cleavage by FeEDTA-generated hydro-
xyl radicals and the subsequent primer extension analysis were
carried out as described [20–23].
2.3. Rapid kinetics analyses
MF-mRNA (or ﬂuorescein-labeled MF-mRNA)-programmed
pre-translocation complexes carrying deacylated tRNAfMet and
fMetPhe-tRNAPhe in the P- and A-site, respectively, were prepared
as described [24]. Fluorescence stopped-ﬂow analyses were per-
formed in 50 mM Tris–HCl (pH 7.5), 70 mM NH4Cl, 30 mM KCl,
7 mM MgCl2 by rapidly mixing at 37 C equal volumes (50 ll) of
pre-translocation complex (0.2 lM in syringe 1) with or without
antibiotic (20 lM) with EF-GGTP (4 lM in syringe 2). Pi release
from EF-G following GTP hydrolysis was monitored by the
ﬂuorescence change of MDCC-labeled phosphate-binding protein
(PBP–MDCC) as described [24].
3. Results
When searching the proprietary ABL database [25], which con-
tains properties of known microbial metabolites, we noticed that
GE82832 showed a similar molecular mass and identical UV–vis
spectrum to dityromycin, an antibiotic whose molecular structure
had been elucidated over 30 years ago [16,17]. Although the genus
Streptosporangium (the producer of GE82832) is distantly related to
the genus Streptomyces (the producer of dityromycin), many prece-
dents exist of representatives of the same chemical class produced
by distant genera of Actinobacteria (e.g., glycopeptides) [26].
The correspondence between GE82832 and dityromycin was
conﬁrmed by the functional tests carried out in parallel with the
two molecules. Indeed, GE82832 and dityromycin yielded essen-
tially superimposable dose–response curves in the inhibition of
mRNA translation and fMet-Phe-puromycin formation (Fig. 1). Fur-
thermore, the topographical localization of GE82832 and dityro-
mycin seems to be the same, as judged from the identical in situ
hydroxyl radical cleavage pattern obtained in the presence of thetwo antibiotics (Fig 2A,B,C). These experiments show that both
antibiotics affect the accessibility of the hydroxyl radicals in 16S
rRNA helices h42 and h43 which are located in the head domain
of the 30S subunit. Indeed, the accessibility of bases belonging to
h42 located in proximity of ribosomal protein S13 is affected by
the antibiotics with U1326 becomingmore exposed to the cleavage
while C1328 and A1329 are protected. In addition, also protected
are the bases comprised between 1337 and 1340; these bases are
located in a portion of the 30S forming part of the P-site gate
and involved, together with the N-terminal portion of S13 and
H38 of 23S rRNA, in the formation of inter-subunit bridge B1
[27]. Furthermore, the two antibiotics protect from cleavage bases
belonging to h43. These are A1346, U1351, C1352 which are also
located near S13 but in a more internal portion of the 30S head.
These results not only are in agreement with the results of the
DMS chemical probing which indicated that GE82832 protects
A1324 and A1333 while exposing C1336 [15], but also demon-
strate that the binding of the two antibiotics affects the structure
of a broader region of the head of the 30S subunit, spanning from
protein S19 to part of the gate forming the P-site and centered
around protein S13, which represents a key element for amino-
acyl-tRNA/mRNA translocation [28].
Thus, these results indicate that in addition to targeting with
the same efﬁciency the same translational function, the two antibi-
otics have the same topographical localization and/or produce
identical structural changes on the 30S ribosomal subunit.
On the basis of these results the two molecules were subjected
to further comparisons. Due to the limited availability of both
GE82832 and dityromycin, comparisons were based on LC–MS
analyses of the intact compounds and after parallel chemical reac-
tions. LC analyses (see Material and Methods) conﬁrmed that both
dityromycin and GE82832 elute as complexes of two isomeric sub-
stances with similar retention times (4.6 and 4.4 min, respec-
tively), thus showing comparable lipophilicity. Furthermore, both
dityromycin congeners showed UV spectra (with maxima at 280
and 310 nm), consistent with literature data [16,17] and superim-
posable on those measured for both GE82832 congeners (data not
shown). MS analysis of dityromycin in positive ionization mode
presented a monocharged ion at m/z 1311, corresponding to the
sodiated molecule [M+Na]+ while negative ionization mode led to
an ion at m/z 1401, corresponding to the triﬂuoroacetic acid ad-
duct. These data are consistent with the mass of 1288 amu re-
ported by O¯mura’s laboratory [16,17]. Under the same ionization
conditions, GE82832 showed monocharged ions of m/z 1309 and
Fig. 2. Comparison of the in situ accessibility of 16S rRNA in the presence of GE82832 and dityromycin The topographical localization of GE82832/dityromycin on the 30S
ribosomal subunit was determined from the primer extension analysis of the cleavage sites generated on the 16S rRNA in situ by hydroxyl radicals in the presence of
increasing concentrations of GE82832 (left) and dityromycin (right). The bases protected and more exposed in the presence of GE82832 and dityromycin are indicated at the
right-hand side of the gels in blue and red script, respectively. The lanes G, A, K, C correspond to sequencing lanes (G, A) and to the 16S rRNA not subjected to cleavage (K) or
subjected to cleavage in the absence of antibiotics (C). (B) The topographical localization of ribosomal protein S13 (green) and of the sites whose accessibility is increased
(red) or decreased (blue) in the presence of GE82832/dityromycin are indicated within the 3D structure of the 30S ribosomal subunit (PDB ﬁle 1YL4); (C) close-up view of the
localization of S13 and of the 30S ribosomal subunit sites protected and more exposed in the presence of GE82832/dityromycin. The color code is the same as in panel (B).
Further details can be found in Ref. [23].
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consistent with a 2-amu difference between GE82832 and dityro-
mycin. A close structural relationship between the two molecules
is further strengthened by MS/MS experiments, which yielded
the same fragmentation pattern for GE82832 and dityromycin
(Fig. 3A,B). Both molecules were then reacted with AcOH: 37%
HCl 25:1 (v/v) at room temperature. After 10 min, LC–MS revealed
the disappearance of the starting compounds and the formation of
lipophilic derivatives in a 1:1 ratio, having [M+Na]+ at m/z 1347
and 1383 for dityromycin, and at 1345 and 1381 for GE82832 (data
not shown). The 36-amu differences and the isotopic patterns of
the mass ions suggested that these products were formed by addi-
tion of one (m/z 1347 and 1345) or two molecules (m/z 1383 and
1381) of hydrochloric acid to both dityromycin and GE82832, con-
sistent with the presence of the epoxy-hydroxy-dehydro-isoleu-
cine moiety. Under more drastic conditions, (AcOH:37% HCl 1:1
v/v) smaller fragments, lacking chlorine atoms and having m/z
1148 and 1146, were observed for dityromycin and GE82832,
respectively, probably due to the loss of the halogenated residuefollowed by a dehydration. A preliminary NMR spectrum, obtained
on a partially puriﬁed sample of GE82832, highlighted the
presence of signals belonging to a di-tyrosine moiety in a peptide
structure containing also signals assignable to N-methyl valine,
N,N-dimethyl-threonine and phenylglycine, residues that are also
found in dityromycin (Fig. S1 and Table S1).
All these data strongly suggest that the structure of GE82832 is
identical to that of dityromycin (Fig. 3C), but for the presence of
minor chemical differences. The 2-amu difference might result
from an additional unsaturation present somewhere in GE82832.
However, alkaline treatment of the two molecules (1 M NaOH)
showed the formation of smaller fragments having m/z 753 and
737 for dityromycin and GE82832, respectively, suggesting that
the 2-amu difference may originate from a combination of at least
two modiﬁcations in different parts of the molecule. To discrimi-
nate among the various possibilities, further investigations are
necessary on larger amounts of puriﬁed compounds.
The following experiments were carried out to obtain a deeper
understanding of the mechanism by which translocation is
Fig. 3. Comparison of the MS spectra obtained with GE82832 and with dityromycin and chemical structure of dityromycin (A) GE82832; (B) dityromycin; (C) chemical
structure of dityromycin (from [17]). Further details can be found in the text.
Fig. 4. Effect of GE82832/dityromycin on the ribosome and EF-G-dependent GTP hydrolysis and Pi release. (A) Multiple turnover EF-G-dependent GTP hydrolysis; (B) single
round EF-G-dependent GTP hydrolysis in the presence (d) or absence (j) of 20 lM of GE82832/dityromycin; (C and D) Pi release from EF-G-GDP-Pi on a shorter (C) and
longer (D) time-scale. Tracings marked ‘‘1’’ and ‘‘2’’ represent the kinetics recorded in the absence and presence of 20 lM GE82832/dityromycin, respectively. Further
experimental details can be found in materials ad methods.
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with both GE82832 and dityromycin indicate that the antibiotics
do not inhibit the ribosome- and EF-G-dependent hydrolysis of
GTP, either when this activity is measured in a multiple turnover
mode (Fig. 4A) or as single round reaction (Fig. 4B). These data
indicate that the ribosomal binding and afﬁnity of EF-G for the
ribosomes and the activation of the GTPase catalytic center of
the factor are not affected by the antibiotics. On the other hand,the release of Pi from EF-G (Fig. 4C,D) as well as the movement
of both mRNA (Fig. 5A) and aminoacyl-tRNA (Fig. 5B) are substan-
tially slowed down in the presence of the antibiotics, suggesting
that the inhibition occurs at the level of ribosome ‘‘unlocking’’
which precedes these three activities (Fig. 5C).
Finally, the reported antibacterial spectrum of dityromycin (ac-
tive against Bacillus, Corynebacterium and Clostridium, but inactive
against Staphylococcus aureus and Gram-negative bacteria [17] is
Fig. 5. Effect of GE82832/dityromycin on the EF-G-dependent tRNA/mRNA translocation Effect of GE82832/dityromycin on the kinetics of EF-G-dependent (A) mRNA; (B)
aminoacyl-tRNA translocation. Tracings marked ‘‘1’’ and ‘‘2’’ represent the kinetics recorded in the absence and presence of 20 lM GE82832/dityromycin, respectively.
Further experimental details can be found in Materials ad Methods; (C) scheme of the various steps involved in translocation.
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tional indication that GE82832 and dityromycin have essentially
the same structure.
4. Discussion
This study allows us to attribute simultaneously structural
information to an inhibitor for which only the target had been
identiﬁed and a speciﬁc function to an antibiotic for which nothing
but the structure was known. In fact, here we have demonstrated
that the chemical structure of GE82832, the translocation inhibitor
identiﬁed by HTS of a natural library of secondary metabolites of
soil microorganisms [15], corresponds almost completely to that
of dityromycin, an antibiotic whose structure had been elucidated
but whose mechanism of action had never been investigated
[16,17]. The minor difference (two units of mass) detected
between GE82832 and dityromycin is irrelevant for the biological
activity of these two molecules, which displayed identical proper-
ties and activities in all tests performed. In addition, also the
microbiological spectrum of action of GE82832, as determined by
the preliminary tests, proved to be very similar to that reported
for dityromycin [16]. It should be mentioned that cross-linked
Tyr residues similar to that present in GE82832 and dityromycin,
besides being the hallmark of glycopeptides [26], are also present
in plant metabolites such as bouvardin and related compounds
that inhibit protein synthesis in eukaryotes [29].
Furthermore, our data shed light on the mechanism by which
bacterial translocation is inhibited by GE82832/dityromycin.
Translocation proceeds in steps beginning with a pre-translocation
complex (Fig. 5C). Overall, the process is driven, both kinetically
and thermodynamically, by elongation factor G (EF-G) whoseﬁve-domains change conformation upon GTP hydrolysis and
release of inorganic phosphate (Pi), in a process coupled to confor-
mational changes of the ribosome that facilitate the movement of
both aminoacyl-tRNA and mRNA to yield a post-translocation com-
plex (Fig. 5C).
Analysis of the results of the various translocation steps ob-
tained in the presence of GE82832/dityromycin indicates that
these antibiotics do not inhibit the formation of the pre-transloca-
tion complex in which the aminoacyl-tRNAs assume hybrid bind-
ing positions [30], the binding of EF-G-GTP [31], the rotation of
the 30S subunit relative to the 50S subunit and the swiveling mo-
tion of the head of the 30S subunit [32–34] and the activation of
the EF-G-dependent GTP hydrolysis. On the other hand,
GE82832/dityromycin likely interferes with the subsequent step
of translocation, namely the rearrangement or ‘‘unlocking’’ of the
ribosome which allows the movement of aminoacyl-tRNA and
mRNA and the release of Pi from EF-G-GDP [35]. Although these
steps are not strictly linked with one-another and each step can
be inhibited independently [35–37], none of the antibiotics tested
(paromomycin, spectinomycin, hygromycin B, tetracycline, strep-
tomycin) was able to inhibit both steps [37]. Thus, the mechanism
of translocation inhibition by GE82832/dityromycin is special inso-
far as this antibiotic inhibits the movement of both aminoacyl-
tRNA and mRNA and decreases the rate of Pi release.
In light of these ﬁndings we can surmise that GE82832/dityro-
mycin interferes with ribosome-unlocking, a step which entails
an increased mobility of the head of the 30S subunit and is neces-
sary for Pi release and aminoacyl-tRNA/mRNA movement (Fig. 5C).
The effects of GE82832/dityromycin on the accessibility of 16S
rRNA to hydroxyl radical cleavage (Fig. 2) and chemical modiﬁca-
tions [15] near protein S13, in the head region of the subunit, are
3378 L. Brandi et al. / FEBS Letters 586 (2012) 3373–3378fully compatible with the hypothesis that GE82832/dityromycin
might interfere with the internal mobility of the 30S subunit,
which is rate-limiting for translocation [35] rather than with the
ratcheting mechanism of the two subunits as previously suggested
[15].
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